Excellent Pharma Consulting

Excellent is not just part of our name; it is our standard of work! ™
Home
About Us
Contact Us
Site Map
Resources

Regulatory Affairs and Regulatory/Quality Compliance

  • Compliance Evaluation and Support (Drugs, Devices, Biologics, In-Vitro Diagnostics, Vaccines)
    • Establishing and improving GxP systems and procedures
    • Assessments for New or Modified Facilities
    • Assessments in Preparation for an FDA, EU or other regulatory inspection
    • Assessments for specific quality and/or manufacturing systems, e.g., change control, documentation, investigations, Part 11, out-of-specification, laboratory compliance, external contract laboratories, efficiency improvements, sterilization, aseptic processing, active pharmaceutical manufacturers (APIs), supplier audits, and so forth.
    • Training in performance of assessments, both from a technical and compliance perspective
    • Training in specific regulatory and/or industry guidance documents
    • Assist in responses to FD483’s, and deficiencies from other regulatory agencies
    • Assist with regulatory letters and regulatory interface
    • Interface with regulators, e.g., ask blinded questions of regulators
    • Returning facilities to compliant operations following regulatory action
  • Regulatory Affairs
    • Preparation of NDAs, ANDAs, PMAs, and 510(k)s
    • Development of Chemistry, Manufacturing and Controls (CMC) sections of regulatory submissions
    • Act as Registered Agent for Foreign Manufacturer’s of Products or APIs
    • Preparation of Sterile Process Validation Packages (aseptic and terminal sterilization)
    • Pre-submission review of drug and device submissions, sterile process validation packages, and documentation
    • Paper and Electronic Submissions for FDA
    • Comparability Protocol preparation for a variety of purposes, e.g.
      • new or remodeled manufacturing lines
      • changes to manufacturing sites
      • changes to contract manufacturing sites
      • changes in testing laboratories
      • new or modified equipment
      • new or remodeled aseptic areas
      • alternative suppliers for components, active pharmaceutical ingredients, new manufacturing locations
      • implementation of rapid microbiological methods
      • implementation of process analytical technologies